Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial

World News: . []

CALGARY, Alberta, June 12, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in , the Company’s event-based, phase 3 registration trial, recently completed their last study visits on treatment. Final, follow-up safety visits are progressing and are expected to be completed by July 4, 2019. Once safety visits have concluded for all patients, Resverlogix anticipates being in a position to provide an updated projected timeframe for top-line data readout.

The remaining steps are amongst those required to assure an orderly, safe and efficient culmination of BETonMACE:

On , BETonMACE successfully reached 250 projected major adverse cardiac events (MACE), strictly defined as cardiovascular death, non-fatal myocardial infarction and stroke, moving the potentially landmark trial towards completion. Successful data from this trial would enable Resverlogix to proceed towards the regulatory approval and commercialization of its lead drug, – a leader in a new class of drugs outside of oncology designed to regulate disease-associated proteins.

Dosing with commenced in November 2015 and the trial exceeded full enrollment – with a total of 2,425 study participants – in March 2018. BETonMACE has been reviewed nine times by the trial’s independent Data and Safety Monitoring Board, with no safety issues identified, and has been recommended to continue without any study modifications. The primary endpoint of the BETonMACE trial is designed to show a relative risk reduction of narrowly defined MACE for patients who remain on a high-dose statin therapy and top standard of care. Despite maximized use, current statin therapies manage about 30% of cardiovascular disease related events leaving a significant market opportunity for apabetalone.

Following a successful BETonMACE trial, the Company is focusing on three initial indications – acute coronary syndrome, vascular cognitive dementia and chronic kidney disease – with an addressable market of over 12 million patients in the top 8 markets.

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX

Investor Relations Email: Phone: 403-254-9252Or visit our website:

More news and information about Resverlogix Corp

Published By:

Globe Newswire: 13:30 GMT Wednesday 12th June 2019

Published: .

Search for other references to "resverlogix" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us